In a relatively quiet quarter of operations that saw production roll back 12% q/q, Trilogy reported 2Q15 results that were slightly behind our expectations on both a cash flow and production basis, however generally aligned with the consensus forecast for the period. The upside of the modest capital undertaking was that cash flow outstripped spending by just over $20 mm, which, when augmented by a non-core Kaybob Dunvegan asset sale ($45 mm) in early 3Q15e, does provide a much needed quart ....